
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical deve... MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1601 | -5.88581302158 | 2.7201 | 2.79 | 2.54 | 3819 | 2.64197015 | CS |
4 | -0.24 | -8.57142857143 | 2.8 | 2.91 | 2.54 | 7001 | 2.76980487 | CS |
12 | -0.19 | -6.90909090909 | 2.75 | 2.91 | 2.3 | 20562 | 2.56739111 | CS |
26 | -0.55 | -17.6848874598 | 3.11 | 3.3339 | 2.3 | 31823 | 2.80097771 | CS |
52 | -1.79 | -41.1494252874 | 4.35 | 4.42 | 2.3 | 46324 | 3.25045171 | CS |
156 | -36.64 | -93.4693877551 | 39.2 | 44.038 | 2.3 | 1042197 | 10.73865507 | CS |
260 | -42.04 | -94.2600896861 | 44.6 | 91.5 | 2.3 | 1070095 | 31.08798723 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約